Format

Send to

Choose Destination
World Allergy Organ J. 2014 Dec 4;7(1):32. doi: 10.1186/1939-4551-7-32. eCollection 2014.

Anti-IL5 therapy for asthma and beyond.

Author information

1
St Joseph's Healthcare & Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6 Canada.

Abstract

Airway inflammation is considered to be the primary component contributing to the heterogeneity and severity of airway disorders. Therapeutic efficacies of diverse novel biologics targeting the inflammatory pathways are under investigation. One such target is IL-5, a type-1 cytokine that is central to the initiation and sustenance of eosinophilic airway inflammation. Over the past decade, anti-IL5 molecules have been documented to have mixed therapeutic benefits in asthmatics. Post hoc analyses of the trials reiterate the importance of identifying the IL-5-responsive patient endotypes. In fact, the currently available anti-IL5 treatments are being considered beyond asthma management; especially in clinical complications with an underlying eosinophilic pathobiology such as hypereosinophilic syndrome (HES) and eosinophilic granulomatosis and polyangitis (EGPA). In addition, closer analyses of the available data indicate alternative mechanisms of tissue eosinophilia that remain uncurbed with the current dosage and delivery platform of the anti-IL5 molecules.

KEYWORDS:

Benralizumab; Chronic bronchitis; Chronic obstructive pulmonary disorder (COPD); Churg-strauss syndrome; Eosinophil; Eosinophilic asthma; Eosinophilic granulamatosis and polyangitis (EGPA); Hypereosinophilic syndrome (HES); IL-5; Mepolizumab; Reslizumab

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center